Showing results (141-150 of 161) with videos related to

Sort By:
Pageof 17
The Journal of Headache and Pain|May 4, 2021
Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)Fabrizio Vernieri, Claudia Altamura, Nicoletta Brunelli, et al.
European Journal of Neurology|November 26, 2021
Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3-month observational, longitudinal, cohort, multicenter, Italian real-life studyFabrizio Vernieri, Claudia Altamura, Nicoletta Brunelli, et al.
Journal of Neurology|June 28, 2022
Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experienceClaudia Altamura, Nicoletta Brunelli, Marilena Marcosano, et al.
The Journal of Headache and Pain|March 23, 2023
Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 studyPiero Barbanti, Gabriella Egeo, Cinzia Aurilia, et al.
Children (Basel, Switzerland)|November 25, 2023
Early Respiratory Physiotherapy versus an Individualized Postural Care Program for Reducing Mechanical Ventilation in Preterm Infants: A Randomised Controlled TrialMilena Tana, Anthea Bottoni, Francesco Cota, et al.
Pediatric Pulmonology|July 13, 2018
Nasal high-frequency oscillatory ventilation and CO2 removal: A randomized controlled crossover trialRoberto Bottino, Federica Pontiggia, Cinzia Ricci, et al.
Journal of Neurology|January 17, 2024
Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational studyPiero Barbanti, Cinzia Aurilia, Gabriella Egeo, et al.
Neurology and Therapy|March 7, 2024
Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 StudyPiero Barbanti, Gabriella Egeo, Stefania Proietti, et al.
Neurology and Therapy|June 9, 2026
Real-World Response and Super-Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III StudyPiero Barbanti, Cinzia Aurilia, Massimo Filippi, et al.
Endocrine Oncology (Bristol, England)|January 17, 2025
NET Models Meeting 2024 white paper: the current state of neuroendocrine tumour research models and our future aspirationsPo Hien Ear, Ilaria Marinoni, Talya Dayton, et al.
Pageof 17